Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sequencing capacity ramp-ups, antibody pipeline milestones, and cash-burn assumptions make Twist Bioscience’s SEC disclosures uniquely complex. Locating gene-synthesis revenue mix in the Twist Bioscience annual report 10-K simplified filing or tracing collaboration updates buried in an 8-K often means scrolling through hundreds of pages. Stock Titan solves this pain point by turning dense biotechnology jargon into concise insights, giving you twist bioscience SEC filings explained simply without losing critical detail.
Our AI reads every document the instant it hits EDGAR, delivering Twist Bioscience Form 4 insider transactions real-time, red-flagging risk-factor changes, and extracting segment metrics into dashboards. Whether you’re searching for a twist bioscience quarterly earnings report 10-Q filing, a sudden twist bioscience 8-K material events explained, or the latest twist bioscience proxy statement executive compensation tables, the platform highlights exactly where the numbers live and what they mean. Smart tags link cash-flow shifts to R&D spending so you can perform twist bioscience earnings report filing analysis in minutes, not hours.
Need to monitor management moves before the next capital raise? Track every twist bioscience insider trading Form 4 transactions alert or dive deeper into twist bioscience executive stock transactions Form 4 to spot buying trends. From cost-of-goods disclosures that impact gross margin to litigation notes that could reshape IP value, our expert commentary keeps you ahead. If you’re focused on understanding Twist Bioscience SEC documents with AI, start here—comprehensive coverage, real-time updates, and plain-English explanations for every filing type.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a non-discretionary sale on 09/22/2025 to satisfy tax withholding for vested restricted stock units. The filing shows 233 shares disposed at $27.56 per share and the reporting person held 102,710 shares following the transaction. The sale is described as a company-mandated "sell to cover" tied to equity plan withholding, not a voluntary trade by the insider.
The Form 4 was signed on 09/24/2025 by an attorney-in-fact. No other transactions or derivative positions are reported in this filing.
Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corporation (TWST), reported a sale of 295 shares of TWST common stock on 09/22/2025 at an average price of $27.56 per share, leaving her with 124,542 shares beneficially owned. The filing indicates the sale was a mandatory "sell to cover" transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units rather than a discretionary trade by the reporting person. The Form 4 was signed by an attorney-in-fact and submitted on 09/24/2025. The transaction is routine for equity compensation settlements and does not, by itself, indicate a change in officer ownership intent.
Emily M. Leproust, CEO and Director of Twist Bioscience (TWST), reported a non-discretionary sale and her current holdings. The filing shows a sale of 1,704 shares of Twist common stock on 09/22/2025 at $27.56 per share performed to satisfy tax-withholding required under the company's equity plans. After that transaction she beneficially owns 633,036 shares directly. The form also lists outstanding employee stock options with exercise prices and post-transaction holdings: $5.95 (0), $8.82 (150,879), $26.66 (266,539), $23.33 (131,290) and $67.85 (64,950). The filing notes one set of performance stock options vested and became exercisable on 12/19/2022.
Twist Bioscience (TWST) Form 144 summary: A notice was filed for a proposed sale of 1,704 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $46,962.07 and an approximate sale date of 09/22/2025. The filing states these shares were acquired on 09/22/2025 as restricted stock vesting and the payment type is listed as compensation. The issuer's number of shares outstanding is reported as 60,360,925.
The filing also discloses four prior sales by Emily M. Leproust during the past three months totaling 11,042 shares for aggregate gross proceeds of $304,506.36. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information about the issuer.
Twist Bioscience Corp (TWST) notice of proposed sale reports that 295 common shares will be offered through Fidelity Brokerage Services with an aggregate market value of $8,130.17. The filing states the shares were acquired on 09/19/2025 by restricted stock vesting and were paid as compensation on that date. The filing lists approximately 60,360,925 shares outstanding and an intended sale date of 09/22/2025 on NASDAQ.
The filer also reported four sales of common stock by Paula Green in the prior three months totaling 2,908 shares for gross proceeds of $79,786.04 (sales on 07/02/2025, 08/04/2025, 08/21/2025 and 09/08/2025). Other contact and issuer-identifying fields in the form appear blank or not provided in the content.
Twist Bioscience (TWST) Form 144 shows a proposed sale of 233 common shares valued at $6,421.46 to be executed on 09/22/2025 through Fidelity Brokerage Services on NASDAQ. The shares were acquired on 09/19/2025 via restricted stock vesting and were paid as compensation.
The filer, identified in the notice as Dennis H. Cho, also reported five prior open-market sales in the past three months totaling 1,794 shares for aggregate gross proceeds of $49,627.58 (sales between 07/02/2025 and 09/15/2025). The filing includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a non-discretionary sale of shares on 09/15/2025 to satisfy tax withholding tied to vested restricted stock units. The reported transaction lists a price of $25.328 per share and shows 102,943 shares beneficially owned by the reporting person after the transaction. The filing was signed by an attorney-in-fact on 09/17/2025. The form states the sale was a mandated "sell to cover" required by the issuer's equity incentive plan and not a discretionary trade by the reporting person.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corporation (TWST), reported a sale on 09/08/2025. The Form 4 shows a non-discretionary sell-to-cover transaction of 269 shares of common stock at $25.76 per share to satisfy tax withholding obligations arising from Restricted Stock Unit vesting. Following the transaction, the reporting person beneficially owns 103,037 shares directly. The filing was signed by an attorney-in-fact on behalf of the reporting person on 09/10/2025.
Twist Bioscience insider sale to cover taxes; reporting confirms compliance. The filing shows Paula Green, SVP of Human Resources and a company officer, had 892 shares sold on 09/08/2025 at $25.76 per share to satisfy tax-withholding obligations arising from the vesting of Restricted Stock Units. After the transaction, the reporting person beneficially owned 124,837 shares, held directly. The sale is described as a mandatory "sell-to-cover" under the issuer's equity plan and therefore is not a discretionary trade by the reporting person. The Form 4 was signed by an attorney-in-fact on 09/10/2025.
Emily M. Leproust, CEO and Director of Twist Bioscience (TWST), reported a routine insider transaction. The filing shows a sale of 2,265 shares of Twist common stock on 09/08/2025 at $25.76 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units; these sales were mandated by the issuer's sell-to-cover election and are not discretionary trades. After the sale, the reporting person beneficially owns 634,740 shares. The form also lists outstanding employee stock options at various exercise prices and vesting schedules, including exercisable options with a $67.85 strike covering 64,950 shares.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
